US2021346448A1PendingUtilityA1
Therapy for promoting cell growth
Est. expiryMar 27, 2029(~2.7 yrs left)· nominal 20-yr term from priority
A61K 36/537A61K 45/06A61K 36/736A61K 36/882A61K 36/481A61P 25/24A61K 36/286A61P 25/14A61P 9/10A61K 36/69A61K 36/236A61K 35/62A61P 43/00A61P 25/28A61K 38/00A61P 21/00A61P 9/00A61K 36/232A61P 25/02A61P 25/00A61P 21/02A61P 25/08A61P 25/06A61K 36/65
69
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells.
Claims
exact text as granted — not AI-modified1 .- 73 . (canceled)
74 . A composition comprising the following four herbal components:
i) Radix Astragali; ii) Radix Polygalae; iii) Rhizoma Chuanxiong ; and iv) Radix Angelicae sinensis,
wherein i, ii, iii, and iv are present in the composition in a ratio of about 5:1:1:1 by weight, respectively.
75 . A composition consisting essentially of the following four herbal components:
i) Radix Astragali; ii) Radix Polygalae; iii) Rhizoma Chuanxiong ; and iv) Radix Angelicae sinensis,
wherein i, ii, iii, and iv are present in the composition in a ratio of about 5:1:1:1 by weight, respectively.
76 . An extraction product of a composition comprising the following four herbal components:
i) Radix Astragali; ii) Radix Polygalae; iii) Rhizoma Chuanxiong ; and iv) Radix Angelicae sinensis,
wherein i, ii, iii, and iv are present in the composition in a ratio of about 5:1:1:1 by weight, respectively.
77 . An extraction product of a composition consisting essentially of the following four herbal components:
i) Radix Astragali; ii) Radix Polygalae; iii) Rhizoma Chuanxiong ; and iv) Radix Angelicae sinensis,
wherein i, ii, iii, and iv are present in the composition in a ratio of about 5:1:1:1 by weight, respectively.
78 . The composition according to claim 74 , wherein said composition is a pharmaceutical composition comprising a pharmaceutically acceptable additive, carrier or diluent.
79 . The composition according to claim 75 , wherein said composition is a pharmaceutical composition comprising a pharmaceutically acceptable additive, carrier or diluent.
80 . The product according to claim 76 , wherein said product is a pharmaceutical product comprising a pharmaceutically acceptable additive, carrier or diluent.
81 . The product according to claim 77 , wherein said product is a pharmaceutical product comprising a pharmaceutically acceptable additive, carrier or diluent.
82 . The product according to claim 80 , wherein said pharmaceutical product is administered orally.
83 . The product according to claim 81 , wherein said pharmaceutical product is administered orally.
84 . The product according to claim 80 , wherein said pharmaceutical product is administered orally as one or more tablets or capsules.
85 . The product according to claim 81 , wherein said pharmaceutical product is administered orally as one or more tablets or capsules.
86 . The product according to claim 80 , wherein said pharmaceutical product is used in combination with one or more Western medicines.
87 . The product according to claim 81 , wherein said pharmaceutical product is used in combination with one or more Western medicines.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.